Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

BMO Capital analyst Evan Seigerman has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

In a few weeks, Howard Chang, M.D., Ph.D., will join Amgen, filling both the roles of senior vice president of research and ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

While Amgen's (NASDAQ: AMGN) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...